Tetrahedron Letters (2019)
Update date:2022-07-30
Topics: Ketones Syntheses Experimental PPARγ Thiazolidinedione
Tanis, Steven P.
Colca, Jerry R.
Parker, Timothy T.
Artman, Gerald D.
Larsen, Scott D.
Gadwood, Robert C.
Zeller, James R.
Ketones 2 (MSDC-0160) and 3 (MSDC-0602) had been selected for clinical development, however their initial syntheses were considered suboptimal for application deep into clinical trials. Difficulties ranging from the nature of the starting material, alcohol oxidation problems, epoxide opening regioisomeric issues, and endgame ketone redox problems had been encountered. Direct ketone introduction/maintenance was desired for maximum efficiency and convergence was found to be critically dependent upon the acidity of the nucleophilic species (13, 18) and the use of pre- or post-alkylative oximino-ether/oxime protection (vide infra). Improvements in overall yield for the syntheses of 2 (MSDC-0160) and 3 (MSDC-0602) from 20% (2) and 31% (3) respectively, to 44% (2) and 59% (3) were realized.
View MoreShanggao Ruiya Fine Chemicals Co., Ltd
Contact:+86-795-2592103
Address:Xingguang Nanlu,Shanggao County Industry Park
Chongqing Shuangfeng Chemical Co.,Ltd
Contact:+86-23-49850156
Address:No.663,xuanhua Rd,yongchuan,chongqing,China
Hangzhou innopharma technology Co,.Ltd.(expird)
Contact:+86-13388601988
Address:Room845,lixin building, moganshan road, hangzhou, china
Xi'an Galaxy Chemicals CO., Ltd
Contact:86-29-89380370
Address:No.8, Gaoxin three road, Xi'an city.
KangZhiYuan Pharmaceutical Company Limited
Contact:(Sabrina)86-20-85273232
Address:4th floor, building B, Dadi industry zone, Tangxia, Tianhe, Guangzhou, China
Doi:10.1002/anie.201902504
(2019)Doi:10.1016/j.tetlet.2007.01.064
(2007)Doi:10.1021/om2011358
(2012)Doi:10.1002/ejoc.201101165
(2011)Doi:10.1021/acs.organomet.5b00069
(2015)Doi:10.1021/ja01320a042
(1934)